iData Research

The global Anesthesia, Respiratory, and Sleep (ARS) market is on track to reach $19.2 billion by 2032 📈

The landscape is shifting faster than ever. Between major product recalls and legacy leaders exiting the ventilator and POC spaces, a massive competitive vacuum has opened up for innovators to step in.

Success in 2026 is about the digital monitoring and data-driven tools that are modernizing patient care both in the hospital and at home. 🏥 🏠

Whether you are tracking OSA dominance or the latest in ECMO platforms, our latest report provides the roadmap you need for the next decade.

Get the full market breakdown here: https://idataresearch.com/product/anesthesia-respiratory-and-sleep-therapy-devices-market/?utm_source=fb&utm_medium=social&utm_campaign=gl-ars

The Future of Surgery is Here!

Minimally invasive robotic surgery is transforming healthcare with greater precision, faster recovery times, and fewer complications — and the market is set to hit $30B by 2031

Discover how AI-powered robotics is shaping the next era of surgery.

Read the full 2025–2031 Surgical Robotics Market Report now on our website by clicking the link in our bio!

Discover the top 5 diabetes drugs set to transform treatment in 2025! From once-weekly insulin to innovative GLP-1 and GIP combination therapies, explore how these breakthroughs are improving outcomes, enhancing patient adherence, and reshaping diabetes care. Read the full blog now! https://zurl.co/UQolN

Let us know what you think!

📊 The Changing Landscape of Glucose Monitoring: CGM vs. FGM

The U.S. glucose monitoring market is undergoing significant changes. Continuous glucose monitoring (CGM) systems, long considered the gold standard in diabetes management, were valued at over $6 billion in 2024 and are projected to grow at a 2% CAGR, surpassing $7 billion by 2031. However, a notable shift is happening in the market—flash glucose monitoring (FGM), a more affordable alternative, has grown 45% in the past three years and is expected to nearly double by 2031.

As diabetes rates continue to rise—driven in part by increasing obesity—the demand for glucose monitoring solutions is growing. CGMs offer real-time continuous tracking, providing critical insights for patients on intensive insulin therapy. Meanwhile, FGMs provide a cost-effective option for those who do not require constant monitoring, making diabetes management more accessible.

With market leaders like Dexcom, Abbott, and Medtronic competing in the CGM space and Abbott holding a dominant position in the FGM market, the future of glucose monitoring will be shaped by both technological advancements and pricing strategies. As CGM prices decrease with innovation slowdowns, could this impact the demand for FGM?

📖 Read our latest blog for a deep dive into these emerging trends, market projections, and what this means for the future of diabetes care:https://zurl.co/kbkLU